WallStreetZenWallStreetZen

NASDAQ: MBRX
Moleculin Biotech Inc Stock Forecast, Predictions & Price Target

Analyst price target for MBRX

Based on 3 analysts offering 12 month price targets for Moleculin Biotech Inc.
Min Forecast
$20.00+365.12%
Avg Forecast
$35.00+713.95%
Max Forecast
$45.00+946.51%

Should I buy or sell MBRX stock?

Based on 3 analysts offering ratings for Moleculin Biotech Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MBRX stock forecasts and price targets.

MBRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-12
lockedlocked$00.00+00.00%2024-03-26
lockedlocked$00.00+00.00%2023-12-14

1 of 1

Forecast return on equity

Is MBRX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.81%

Forecast return on assets

Is MBRX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

MBRX revenue forecast

What is MBRX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$71.4M
Avg 2 year Forecast
$42.0M
Avg 3 year Forecast
$87.0M

MBRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MBRX$4.30$35.00+713.95%Strong Buy
AEZS$1.96$15.00+667.26%Buy
CMMB$0.66$7.00+960.61%Strong Buy
BRTX$1.38N/AN/A
BCDA$0.37$4.00+986.96%Buy

Moleculin Biotech Stock Forecast FAQ

Is Moleculin Biotech Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MBRX) stock is to Strong Buy MBRX stock.

Out of 3 analysts, 2 (66.67%) are recommending MBRX as a Strong Buy, 1 (33.33%) are recommending MBRX as a Buy, 0 (0%) are recommending MBRX as a Hold, 0 (0%) are recommending MBRX as a Sell, and 0 (0%) are recommending MBRX as a Strong Sell.

If you're new to stock investing, here's how to buy Moleculin Biotech stock.

What is MBRX's revenue growth forecast for 2026-2028?

(NASDAQ: MBRX) Moleculin Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.

Moleculin Biotech's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MBRX's revenue for 2026 to be $159,089,193, with the lowest MBRX revenue forecast at $159,089,193, and the highest MBRX revenue forecast at $159,089,193. On average, 1 Wall Street analysts forecast MBRX's revenue for 2027 to be $93,466,571, with the lowest MBRX revenue forecast at $93,466,571, and the highest MBRX revenue forecast at $93,466,571.

In 2028, MBRX is forecast to generate $193,816,167 in revenue, with the lowest revenue forecast at $193,816,167 and the highest revenue forecast at $193,816,167.

What is MBRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MBRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is MBRX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MBRX price target, the average MBRX price target is $35.00, with the highest MBRX stock price forecast at $45.00 and the lowest MBRX stock price forecast at $20.00.

On average, Wall Street analysts predict that Moleculin Biotech's share price could reach $35.00 by Apr 12, 2025. The average Moleculin Biotech stock price prediction forecasts a potential upside of 713.95% from the current MBRX share price of $4.30.

What is MBRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MBRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.